US Stock MarketDetailed Quotes

CRL Charles River

Watchlist
  • 134.460
  • -2.440-1.78%
Trading Apr 7 10:26 ET
6.60BMarket Cap672.30P/E (TTM)

About Charles River Company

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The Discovery and Safety Assessment segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Company Profile

SymbolCRL
Company NameCharles River
Listing DateJun 23, 2000
Issue Price16.00
Founded1947
CEOMr. James C. Foster
MarketNYSE
Employees20100
Fiscal Year Ends12-27
Address251 Ballardvale Street
CityWilmington
ProvinceMassachusetts
CountryUnited States of America
Zip Code01887
Phone1-781-222-6000

Company Executives

  • Name
  • Position
  • Salary
  • James C. Foster
  • Chairman of the Board, President and Chief Executive Officer
  • 13.47M
  • Flavia H. Pease
  • Corporate Executive Vice President and Chief Financial Officer
  • 3.15M
  • Birgit Girshick
  • Chief Operating Officer
  • 5.06M
  • Michael Gunnar Knell
  • Corporate Senior Vice President and Chief Accounting Officer
  • --
  • Victoria L. Creamer
  • Corporate Executive Vice President
  • 2.81M
  • Shannon M. Parisotto
  • Corporate Executive Vice President
  • --
  • Joseph W. LaPlume
  • Corporate Executive Vice President, Corporate Development and Strategy
  • 2.98M
  • Virginia M. Wilson
  • Independent Director
  • 345.50K
  • Reshema Kemps-Polanco
  • Independent Director
  • 413.98K
  • Robert J. Bertolini
  • Independent Director
  • 345.50K
  • Richard F. Wallman
  • Independent Director
  • 360.50K
  • George Llado, Sr
  • Independent Director
  • 325.50K
  • George E. Massaro
  • Lead Independent Director
  • 370.50K
  • Dr. Nancy C. Andrews, M.D.,PhD
  • Independent Director
  • 340.50K
  • Dr. Martin W. Mackay, PhD
  • Independent Director
  • 340.50K
  • Dr. Deborah T. Kochevar, D.V.M.,PhD
  • Independent Director
  • 340.50K
  • Dr. Craig B. Thompson,M.D.
  • Independent Director
  • 320.50K

Market Insights

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Unlock Now

Discussing

Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More